^{2nd Middle East Pharmacy and Pharmaceutical Conference}

Neuropharmacology is a scientific study focused on the action of drugs used for psychiatric and neurodegenerative diseases. Neurological diseases occurs due to imbalance in molecular mechanism due to electrical and chemical signaling

disturbance. The primary focus on neuro pharmacological research is to develop novel targets to treat neurological disorders like schizophrenia, Parkinson's disease, epilepsy and hungintons disease. The prevalence of this disease varies from different regions of the country with a mean of 2394 per 1000000 population provided with rough estimation of 30 million people worldwide. Among the diseases, Alzheimer's and Parkinson's disease remains as great challenge in drug discovery. Alzheimer's disease is a neurodegenerative age related disease affecting the memory and disturbs visuospatial skills. Its hallmark includes hyper phosphorylation, glial activation, neurofibrillary tangles and amyloid plaques. Nowadays low educational status, occupational stress and inflammation leads to dementia and finally results in Alzheimer’s disease. On the other hand, genetic predisposition, long period uncontrolled cardiovascular disease, diabetes mellitus and dyslipidemia also promotes amyloid precursor protein formation resulting in Alzheimer's. Currently available drugs used for symptomatic relief but the etiology not cured. Novel approaches targeted to cure the etiology. Also the US FDA has approved few category of drugs which prevents beta-amyloid plaques and also hyper phosphorylation of proteins. The aim of this presentation is to highlight the current targets of this diseases and expected outcomes.